Your account is not claimed yet. You can sign up with ORCID to claim your account.

Patricia M LoRusso (Patricia LoRusso, Patricia Lorusso)

ORCID

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 14

Top Venues

Cancer research communications

Nature medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Kristina A Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A Boerner, Jing Li, Diane E Durecki, Jan Drappatz, Vinay K Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, Susan Percy Ivy, Ranjit S Bindra, Antonio Omuro, Patricia M LoRusso
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer research communications 3 (2) (2023)
Kristina A Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A Boerner, Jing Li, Diane E Durecki, Jan Drappatz, Vinay K Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, Susan Percy Ivy, Ranjit S Bindra, Antonio Omuro, Patricia M LoRusso
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer research communications 3 (2) (2023)
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey S Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kortmansky, Kimberly L Johung, Ranjit S Bindra, Patricia M LoRusso, Kurt A Schalper
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Patricia M LoRusso, Noboru Yamamoto, Manish R Patel, Scott A Laurie, Todd M Bauer, Junxian Geng, Teffany Davenport, Michael Teufel, Jian Li, Mehdi Lahmar, Mrinal M Gounder
The MDM2-p53 antagonist BI 907828 in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study. Cancer discovery (2023)
Jayesh Desai, Guzman Alonso, Se Hyun Kim, Andres Cervantes, Thomas Benjamin Karasic, Laura Medina, Einat Shacham-Shmueli, Rasha Cosman, Alejandro Falcon, Eelke Gort, Tormod Kyrre Guren, Erminia Massarelli, Wilson H Miller, Luis Paz-Ares, Hans Prenen, Alessio Amatu, Chiara Cremolini, Tae Won Kim, Victor Moreno, Sai-Hong Ignatius Ou, Alessandro Passardi, Adrian Sacher, Armando Santoro, Rafal Stec, Susanna Ulahannan, Kathryn C Arbour, Patricia M LoRusso, Jia Luo, Manish R Patel, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T Lin, Stephanie Royer-Joo, Julie Chang, Tomi Jun, Neekesh V Dharia, Jennifer L Schutzman, null null, Sae-Won Han
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nature medicine (2023)
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey S Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kortmansky, Kimberly L Johung, Ranjit S Bindra, Patricia M LoRusso, Kurt A Schalper
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey S Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kortmansky, Kimberly L Johung, Ranjit S Bindra, Patricia M LoRusso, Kurt A Schalper
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael A Carducci, Ding Wang, Christina Habermehl, Matthias Bödding, Felix Rohdich, Floriane Lignet, Klaus Duecker, Oleksandr Karpenko, Linda Pudelko, Claude Gimmi, Patricia M LoRusso
A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors. Cancer research communications 3 (8) (2023)
Timothy Anthony Yap, Patricia M LoRusso, Deborah J Wong, Siwen Hu-Lieskovan, Kyriakos P Papadopoulos, Josefin-Beate Holz, Urszula Grabowska, Cristian Gradinaru, Kin-Mei Leung, Sylwia Marshall, Claire S Reader, Roslin Russell, Richard C A Sainson, Claire J Seal, Christopher J Shepherd, Fiona Germaschewski, Daniel R Gliddon, Omer Stern, Lesley Young, Neil Brewis, Louis Kayitalire, Michelle Morrow
A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Patricia M LoRusso.css-eqlu8i{font-size:small;padding-left:4px;} (Patricia LoRusso, Patricia Lorusso)

Publication Activity (10 Years)

Top Topics

Top Venues

Patricia M LoRusso (Patricia LoRusso, Patricia Lorusso)